CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance

Leukemia

Volumn 19, Issue 2, 2005, Pages 176-182

  Linenberger, M L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute myeloid leukemia (AML); Calicheamicin; CD33; Gemtuzumab ozogamicin (Mylotarg , CMA 676); Immunoconjugate; Targeted therapy

Indexed keywords

ABC TRANSPORTER; ALPHA INTERFERON; ANTIBODY CONJUGATE; ANTINEOPLASTIC ANTIBIOTIC; CALICHEAMICIN; CALICHEAMICIN DERIVATIVE; CALICHEAMICIN GAMMA1; CASPASE 9; CBL PROTEIN; CD33 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC AGENT; DNA DEPENDENT PROTEIN KINASE; GEMTUZUMAB OZOGAMICIN; GO; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE H2A; INTERLEUKIN 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TUMOR ANTIGEN; UNINDEXED DRUG; VAV PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BONE MARROW CULTURE; CANCER INHIBITION; CELL DEATH; CELL LINE; CELL STRAIN HL 60; CHILL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DNA DAMAGE; DNA REPAIR; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; HYPOTENSION; IN VITRO STUDY; INTERNALIZATION; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; SCID MOUSE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 13544266555     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403598     Document Type: Review

References (95)

1. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004; 100: 441-454.
2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992; 52: 6761-6767.
3. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992; 54: 829-833.
4. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002; 13: 47-58.
5. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002; 13: 40-46.
6. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al, for the Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
7. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627-1636.
8. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490-1496.
9. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095-2104.
10. de Vetten MP, Jansen JH, van der Reijden BA, Berger MS, Zijlmans JM, Lowenberg B. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). Br J Haematol 2000; 111: 277-279.
11. Estey EH, Giles FJ, Beran M, O'Brien S, Pierce SA, Faderl SH et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
12. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343-4349.
13. Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ et al. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 2002; 30 23-28.
14. Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003; 27: 887-891.
15. Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003; 27: 893-897.
16. Tsimberidou A, Estey E, Cortes J, Thomas D, Faded S, Verstovsek S et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003; 97: 1481-1487.
17. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003; 102: 4277-4283.
18. Zwaan CM, Reinhardt D, Corbacioglu S, van Wering ER, Bokkerink JP, Tissing WJ et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003; 101: 3868-3871.
19. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406-413.
20. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99: 2310-2314.
21. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582.
22. Naito K, Takeshita A, Shigeno K, Nakamura S, Fujisawa S, Shinjo K et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 2000; 14: 1436-1443.
23. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multi drug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-994.
24. Matsui H, Takeshita A, Naito K, Shinjo K, Shigeno K, Maekawa M et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813-819.
25. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466-1473.
26. Amico D, Barbui AM, Erba E, Rambaldi A, Introna M, Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003; 101: 4589-4597.
27. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004; 103: 4276-4284.
28. Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004; 18: 316-325.
29. van der Velden VHJ, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004; 18 983-988.
30. van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger AS et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
31. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995; 85: 2005-2012.
32. Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol 2002; 12: 609-615.
33. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 1999; 274: 11505-11512.
34. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 1999; 29: 3440-3449.
35. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483-490.
36. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 × anti-CD64 antibody on proliferation and signaling in myeloid cells. Leuk Res 2001; 25: 1115-1125.
37. Balaian L, Zhong R-k, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with the Syk and/or ZAP-70 expression. Exp Hematol 2003; 31: 363-371.
38. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-132.
39. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984; 8: 521-534.
40. Brendel C, Neubauer A. Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia 2000; 14: 1711-1717.
41. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048-1053.
42. Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118: 560-566.
43. Leone G, Rutella S, Voso MT, Fianchi L, Scardocci A, Pagano L. In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. Haematologica 2004; 89: 634-636.
44. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
45. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000; 14: 474-475.
46. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41: 1206-1214.
47. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678-3684.
48. Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 2001; 21: 1175-1180.
49. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 1998; 4: 1421-1428.
50. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003; 17: 314-318.
51. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol 1999; 36: 2-8.
52. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9: 478-490.
53. van der Jagt RHC, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 1992; 52: 89-94.
54. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996; 56: 2123-2129.
55. McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA. Immunotoxin resistance in multidrug resistant cells. Cancer Res 2003; 63: 72-79.
56. Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin-gamma-1. J Am Chem Soc 1987; 109: 3464-3466.
57. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 2003; 3 386-390.
58. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 11: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198-1201.
59. Myers AG, Cohen SB, Kwon BM. A study of the reaction of calicheamicin gamma(1) with glutathione in the presence of double-stranded DNA. J Am Chem Soc 1994; 116: 1255-1277.
60. Elmroth K, Nygren J, Måtensson S, Ismail HI, Hammarsten O. Cleavage of cellular DNA by calicheamicin gamma1. DNA Repair 2003; 2: 363-374.
61. Walker S, Landovitz R, Ding WD, Ellestad GA, Kahne D. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci USA 1992; 89: 4608-4612.
62. Krishnamurthy G, Brenowitz MD, Ellestad GA. Salt dependence of calicheamicin-DNA site-specific interactions. Biochemistry 1995; 34: 1001-1010.
63. Zhao B, Konno S, Wu JM, Oronsky AL. Modulation of nicotinamide adenine dinucleotide and poly (adnosine diphosphoribose) metabolism by calicheamicin gamma 1 in human HL-60 cells. Cancer Lett 1990; 50: 141-147.
64. Battigello J-MA, Cui M, Roshong S, Carter BJ. Enediyne-mediated cleavage of RNA. Bioorg Med Chem 1995; 3: 839-849.
65. Mårtensson S, Nygren J, Osheroff N, Hammarsten O. Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiat Res 2003; 160: 291-301.
66. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002; 12: 162-169.
67. Watanabe CMH, Supekova L, Schultz PG. Transcriptional effects of the potent enediyne anti-cancer agent Calicheamicin gamma(I)(1). Chem Biol 2002; 9: 245-251.
68. Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G et al. Induction of apoptosis by enediyne antibiotic calicheamicin thetall proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene 2003; 22: 9107-9120.
69. Sullivan N, Lyne L. Sensitivity of fibroblasts derived from ataxiatelangiectasia patients to calicheamicin gamma 11. Mutat Res 1990; 245: 171-175.
70. van Duijn-Goedhart A, Zdzienicka MZ, Sankaranarayanan K, van Buul PPW. Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin. Mutat Res 2000; 471: 95-105.
71. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5: 27-36.
72. Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol 1997; 8: 151-159.
73. Durr FE, Wallace RE, Testa RT, Kuck NA. Biological activities of calicheamicin. In: Borders DB, Doyle TW (eds). Enediyne Antibiotics as Antitumor Agents. New York: Marcel Dekker, 1995, pp 127-136.
74. van der Kolk DM, de Vries EGE, Müller M, Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 2002; 43: 685-701.
75. Legrand O, Zittoun R, Marie J-P. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia 1999; 13: 578-584.
76. Abbott BL. ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 2003; 21: 115-130.
77. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11: 294-303.
78. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
79. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol 2003; 123: 850-857.
80. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
81. Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98: 3575-3583.
82. Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
83. Tsimberidou AM, Estey E, Whitman GJ, Dryden MJ, Ratnam S, Pierce S et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994.
84. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E et al. Gentuzumab ozogamicin ('mylotarg') as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.
85. Candoni A, Damiani D, Michelutti A, Masolini P, Michieli M, Michelutti T et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia. Eur J Haematol 2003; 71: 1-8.
86. Amadori S, Suciu S, Willemze R, Mandelli F, Selleslag D, Stauder R et al. EORTC leukemia group; GIMEMA leukemia group. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004; 89: 950-956.
87. Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004; 28: 987-990.
88. Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003; 52: 449-452.
89. Nabhan C, Rundhaugen L, Jatoi M, Riley MB, Boehlke L, Peterson LC et al. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol 2004; 15: 1231-1236.
90. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17: 468-470.
91. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807-1814.
92. 1. Cancer Res 2000; 60: 6089-6094.
93. Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML et al. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 2003; 52 243-248.
94. Walter RB, Raden BW, Thompson J, Flowers DA, Kiem HP, Bernstein ID et al. Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma 1 in acute myeloid leukemia cells. Leukemia 2004; 18: 1914-1917.
95. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2004; September 28 [E-pub ahead of print].